Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

NCT04230499 is registered in ClinicalTrials.gov with Rapamycin Holdings Inc. as lead sponsor.

NCT NCT04230499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Lead sponsor
Rapamycin Holdings Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 18, 2021
Completion date
March 31, 2025
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

familial adenomatous polyposis